SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.
Huntington's disease (HD) is a devastating neurodegenerative disorder for which there are no disease-modifying treatments. The molecular pathogenesis of HD is complex and many mechanisms and cellular processes have been proposed as potential sites of therapeutic intervention. However, prior to...
Main Authors: | Anna Bobrowska, Gizem Donmez, Andreas Weiss, Leonard Guarente, Gillian Bates |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3325254?pdf=render |
Similar Items
-
Correction: SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo.
by: Anna Bobrowska, et al.
Published: (2021-01-01) -
SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo
by: Bobrowska, Anna, et al.
Published: (2012) -
Validation of HDAC6 and SIRT2 tubulin deacetylases as therapeutic targets for Huntington's disease
by: Bobrowska, Anna
Published: (2012) -
Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
by: Anna Bobrowska, et al.
Published: (2011-01-01) -
Loss of Deacetylation Enzymes Hdac6 and Sirt2 Promotes Acetylation of Cytoplasmic Tubulin, but Suppresses Axonemal Acetylation in Zebrafish Cilia
by: Paweł K. Łysyganicz, et al.
Published: (2021-06-01)